Hologic, Inc. (HOLX) Q4 2022 Results - Earnings Call Transcript

Hologic, Inc. (NASDAQ:HOLX) Q4 2022 Earnings Conference Call October 31, 2022 4:30 PM ET

Company Participants

Ryan Simon - VP, IR

Stephen MacMillan - Chairman, President and CEO

Karleen Oberton - CFO

Conference Call Participants

Patrick Donnelly - Citi

Tejas Savant - Morgan Stanley

Anthony Petrone - Mizuho Group

Jack Meehan - Nephron Research

Puneet Souda - SVB Securities

Liza Garcia - UBS

Max Masucci - Cowen and Company

Tim Daley - Wells Fargo

Derik de Bruin - Bank of America

Casey Woodring - JPMorgan

Operator

Good afternoon and welcome to the Hologic’s Fourth Quarter Fiscal 2022 Earnings Conference Call. My name is Jennie, and I am your operator for today’s call. Today’s conference is being recorded. All lines have been placed on mute. I would now like to introduce Ryan Simon, Vice President, Investor Relations. Please go ahead.

Ryan Simon

Thank you, Jennie. Good afternoon and thank you for joining Hologic’s fourth quarter fiscal 2022 earnings call. With me today are; Steve MacMillan, the company’s Chairman, President and Chief Executive Officer and Karleen Oberton, our Chief Financial Officer.

Our fourth quarter press release is available now on the Investors section of our website. We will also post our prepared remarks to our website shortly after we deliver them as well as an updated corporate presentation and a replay of this call will be available through November 30th.

Before we begin, we would like to inform you that certain statements we make today will be forward-looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement included in our earnings release and SEC filings.

Also during this call, we will discuss certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release. Two of these non-GAAP measures are: one, organic revenue, which we define as constant currency revenue excluding the divested Blood Screening business and revenue from acquired businesses owned by Hologic for less than one year.

And two, organic revenue, excluding COVID-19, which excludes COVID-19 assay revenue, revenue related to COVID-19 and discontinued product sales in Diagnostics. Finally, any percentage change we discuss will be on a year-over-year basis and revenue growth rates will be in constant currency unless otherwise noted.

Now, I'd like to turn the call over to Steve MacMillan, Hologic's CEO.